Health Catalyst Reports Mixed Q3 2025 Results: Revenue Flat, Profitability Improves

Health Catalyst, Inc. (NASDAQ: HCAT) delivered its Q3 2025 earnings, reporting total revenue of $76.3 million, slightly ahead of expectations but essentially flat year‑over‑year. Adjusted earnings per share came in at $0.06, matching the consensus estimate. On the profitability front, the company recorded adjusted EBITDA of $12.0 million, representing a roughly 64 % increase compared with the same period last year. Within the business segments, technology revenue rose 7 % to $52.1 million, while professional services revenue fell about 12 % to $24.3 million. Though full‑year guidance was reaffirmed for revenue of approximately $310 million and adjusted EBITDA of $41 million, the outlook for Q4 indicates revenue of about $73.5 million—a slight decline from Q3—highlighting persistent headwinds in growth. #HealthTech #HCAT #EarningsReport #ProfitabilityFocus #SlimScan #GrowthStocks #CANSLIM